Lymphoma

On May 27, 2022, the U.S. Food and Drug Administration (FDA) made a groundbreaking decision by approving Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

On May 27, 2022, the U.S. Food and Drug Administration (FDA) approved Kymriah for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Kymriah (tisagenlecleucel) is a groundbreaking chimeric antigen receptor T-cell (CAR-T) therapy that has revolutionized the treatment landscape for certain types of blood cancers.

It was initially approved by the U.S. Food and Drug Administration (FDA) in 2017 and later by the European Medicines Agency (EMA) in 2018.

Kymriah (Tisagenlecleucel) is a type of cancer treatment known as CAR T-cell therapy.

On May 1, 2018, the FDA approved Kymriah for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL). Kymriah is a CAR-T immunotherapy.

Kymriah, also known by its generic name tisagenlecleucel, is a groundbreaking cell therapy used to treat certain types of blood cancers.

Kymriah (tisagenlecleucel) is a groundbreaking CAR-T (Chimeric Antigen Receptor T-cell) therapy developed for the treatment of certain types of blood cancers.

Kymriah (tisagenlecleucel) represents a groundbreaking advancement in the field of immunotherapy. It is a chimeric antigen receptor (CAR) T-cell therapy designed to target CD19, a protein found on the surface of B cells.

Kymriah (tisagenlecleucel) represents a groundbreaking advancement in the field of cancer immunotherapy. As a chimeric antigen receptor T-cell (CAR-T) therapy, Kymriah has set a new benchmark for treating various hematologic malignancies.